Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?

BACKGROUND: The causality of overactive bladder syndrome (OAB) is still not fully understood. Several studies indicate a significant increase of prostaglandin E2 (PGE2) in patients with OAB. However, in order to clarify whether these compounds can help to objectify the clinical diagnosis, further st...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegele, Axel, Knippschild, Sonja, Frohme, Carsten, Hänze, Jörg, Olbert, Peter, Hofmann, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230352/
https://www.ncbi.nlm.nih.gov/pubmed/25370343
http://dx.doi.org/10.1186/1471-2490-14-85

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230352/
https://www.ncbi.nlm.nih.gov/pubmed/25370343
http://dx.doi.org/10.1186/1471-2490-14-85

Ejemplares similares